founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.
Company profile
Ticker
ALPN
Exchange
Website
CEO
Mitchell Gold
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
N30 Pharmaceuticals, Inc., Nivalis Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
AIS Operating Co., Inc. • Alpine Immune Sciences Australia PTY LTD ...
ALPN stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
30 May 24
EFFECT
Notice of effectiveness
24 May 24
EFFECT
Notice of effectiveness
24 May 24
25-NSE
Exchange delisting
20 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
20 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
20 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
20 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
20 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
20 May 24
S-8 POS
Registration of securities for employees (post-effective amendment)
20 May 24
Transcripts
ALPN
Earnings call transcript
2022 Q4
23 Mar 23
ALPN
Earnings call transcript
2022 Q3
14 Nov 22
ALPN
Earnings call transcript
2021 Q2
11 Aug 21
ALPN
Earnings call transcript
2020 Q4
19 Mar 21
ALPN
Earnings call transcript
2020 Q3
12 Nov 20
ALPN
Earnings call transcript
2020 Q2
11 Aug 20
ALPN
Earnings call transcript
2019 Q4
30 Mar 20
ALPN
Earnings call transcript
2019 Q3
13 Nov 19
Latest ownership filings
SC 13D/A
Decheng Capital China Life Sciences USD Fund III, L.P.
21 May 24
SC 13D/A
Frazier Life Sciences VIII, L.P.
21 May 24
4
Jorn Drappa
20 May 24
4
ROBERT E CONWAY
20 May 24
4
James N Topper
20 May 24
4
Peter A. Thompson
20 May 24
4
Xiangmin Cui
20 May 24
4
James Paul Rickey
20 May 24
4
STANFORD L PENG
20 May 24
4
MITCHELL GOLD
20 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 33.28 mm | 33.28 mm | 33.28 mm | 33.28 mm | 33.28 mm | 33.28 mm |
Cash burn (monthly) | 3.64 mm | (no burn) | 7.57 mm | 3.90 mm | 9.23 mm | 6.71 mm |
Cash used (since last report) | 24.43 mm | n/a | 50.85 mm | 26.24 mm | 62.04 mm | 45.12 mm |
Cash remaining | 8.85 mm | n/a | -17.57 mm | 7.05 mm | -28.76 mm | -11.84 mm |
Runway (months of cash) | 2.4 | n/a | -2.3 | 1.8 | -3.1 | -1.8 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 179 |
Opened positions | 103 |
Closed positions | 13 |
Increased positions | 42 |
Reduced positions | 24 |
13F shares | Current |
---|---|
Total value | 2.04 tn |
Total shares | 71.43 mm |
Total puts | 199.40 k |
Total calls | 158.40 k |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
Decheng Capital China Life Sciences USD Fund III | 6.58 mm | $79.38 mm |
Avoro Capital Advisors | 5.78 mm | $228.92 bn |
BLK BlackRock | 3.58 mm | $141.72 bn |
Frazier Life Sciences VIII | 3.20 mm | $44.95 mm |
Frazier Life Sciences Management | 3.13 mm | $124.11 bn |
T. Rowe Price | 3.08 mm | $122.10 mm |
STT State Street | 2.85 mm | $112.81 bn |
Vanguard | 2.71 mm | $107.51 bn |
Cormorant Asset Management | 2.70 mm | $107.03 bn |
Orbimed Advisors | 2.68 mm | $106.25 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 May 24 | Remy Durand | Common Stock | Sale back to company | Dispose D | No | No | 0 | 31,200 | 0.00 | 0 |
20 May 24 | Remy Durand | Common Stock | Sale back to company | Dispose D | No | No | 0 | 102,192 | 0.00 | 31,200 |
20 May 24 | Remy Durand | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 18.33 | 78,000 | 1.43 mm | 0 |
20 May 24 | Remy Durand | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 7.55 | 109,000 | 822.95 k | 0 |
20 May 24 | Remy Durand | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 13.3 | 112,500 | 1.50 mm | 0 |
20 May 24 | Remy Durand | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 13.2 | 70,155 | 926.05 k | 0 |
20 May 24 | Remy Durand | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.23 | 26,922 | 86.96 k | 0 |
20 May 24 | Remy Durand | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.09 | 2,635 | 10.78 k | 0 |
20 May 24 | Ulrich Martin Fuhs | Common Stock | Sale back to company | Dispose D | No | No | 0 | 7,300 | 0.00 | 0 |
20 May 24 | Ulrich Martin Fuhs | Common Stock | Sale back to company | Dispose D | No | No | 0 | 22,820 | 0.00 | 7,300 |